China has approved a product for rheumatoid arthritis and Crohn disease that Mabpharm and Sorrento Therapteutics say is an improvement on infliximab.
Has a Chinese company come up with an improvement on infliximab, the immunosuppressive drug used to treat rheumatoid arthritis, Crohn disease, and ulcerative colitis, among other conditions?
Mabpharm, of Taizhou, and its commercialization partner Sorrento Therapeutics, of California, said China’s National Medical Products Administration has granted Mabpharm approval to market a “biobetter” (CMAB008) for infliximab in China.
Biobetters are drugs that have similar structure and properties to an innovator product but are enhanced or modified to produce better outcomes. In a statement, Sorrento said the antibody biobetter was developed with Chinese hamster ovary cells, vs mouse cells for infliximab, and “has demonstrated a better safety profile…while maintaining [infliximab’s] efficacy profile.”
Sorrento has been granted rights to commercialize the product outside China and said it would now approach regulators in the United States and Europe for guidance on filing for marketing approval.
In the United States and the European Union, in addition to the originator product, Remicade (Janssen), there are several infliximab biosimilars on the market, including Renflexis (Merck, Samsung Bioepis), Avsola (Amgen), and Inflectra (Celltrion, Pfizer).
Market Dynamics
The arrival of a biobetter could shake up demand for the originator product and its biosimilars, and this highlights one of the challenges for biosimilar makers.
By the time biosimilars come on the market, an originator company has enjoyed a long run of profits, presumably more than compensating for research and development expense, but this may not be the case for biosimilar companies.
Biosimilar developers may invest as much as $200 million in development of a biosimilar and could immediately face competition from other biosimilars, costly litigation from originator companies, and heavy pressure to reduce prices.
Avsola, for example, launched in the United States just a year ago, in July 2020. Inflectra and Renflexis launched in the United States in 2016 and 2017, respectively, and their makers have enjoyed a longer run of sales revenue.
However, in the United States infliximab biosimilars have been among the slowest of biosimilars to take off. They commanded just 23% of the market for infliximab by the close of the first quarter of 2021, according to Amgen.
Competition and pricing pressures have also battered the returns on these products for drug makers. Infliximab biosimilar average sales prices (ASPs) have declined roughly 45% since these biosimilars were first introduced in the United States, whereas the ASP for Remicade has experienced a drop of greater than 40%, according to Amgen data.
Remicade notched revenues of $3.7 billion in 2020, down from $4.4 billion the previous year, according to a Johnson & Johnson earnings statement. Sorrento estimated that total 2020 infliximab sales, including biosimilars, were $4.2 billion.
In the rapidly changing field of oncology, where the pace of treatment advances is high, the business risks are more acute. For this reason, pharmaceutical companies may adopt a cautious stance toward developing biosimilars for use in oncology.
Treatment of Last Resort
Infliximab is an anti–tumor necrosis factor (TNF) antibody that targets inflammation characteristic of arthritic and gastrointestinal disorders. “It is usually prescribed when other medicines or treatments have failed,” which makes it an important treatment of last resort, Sorrento noted in its statement.
Sorrento said the Mabpharm biobetter has not only an improved safety profile but also lower immunogenicity compared with infliximab. “The Chinese approval covers 6 different indications, including adult ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, adult and childhood Crohn disease, fistula Crohn disease, and psoriasis,” the company said.
Sorrento was described as a clinical stage, antibody-centric biopharmaceutical company geared toward developing therapies for cancer and COVID-19.
Mabpharm describes itself as a biopharmaceutical company with a focus on development and production of new drugs and biosimilars for cancer and autoimmune diseases.
Mabpharm has multiple monoclonal antibody drugs (both biobetter and biosimilar candidates) in development, including versions of omalizumab (asthma), cetuximab (colorectal cancer), trastuzumab (breast, metastatic gastric cancer), and nivolumab (non–small cell lung and hepatocellular cancers).
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.